No Data
Change in shareholding report for Shin Bio Pharma (9.26% → 7.35%) by CANTOR FITZGERALD.
Filer: CANTOR FITZGERALD EUROPE Filing Date and Time: March 4, 2026, 14:18 Document Filed: Amendment Report (Cover Page = Amendment Report No. 8) Report Obligation Trigger Date: February 27, 2026 Reason for Amendment Report Submission: The holding ratio of shares, etc., decreased by more than 1%, and there was a change in the breakdown of the held shares. Issuer: <4582> Shin Bio Pharmaceutical Co., Ltd.
Change in shareholding report: Shinbio Pharmaceutical (13.68% → 9.26%) CANTOR FITZGERALD.
Submitter: CANTOR FITZGERALD EUROPE Submission Date and Time: March 2, 2026, 13:03 Submitted Document: Amendment Report (Cover Page = Amendment Report No. 7) Reporting Obligation Trigger Date: February 24, 2026 Reason for Filing Amendment Report: The holding percentage of stock certificates increased by more than 1%, and there were changes in significant contracts such as security agreements related to the stock certificates. Issuer: <4582
Change in shareholding report for SymBio Pharma (25.91% → 25.23%) by Evo Fund, etc.
Submitter: Evo Fund Submission Date and Time: February 26, 2026, 13:57 Submitted Document: Amendment Report (Cover Page = Amendment Report No. 18) Reporting Obligation Trigger Date: February 18, 2026 Reason for Amendment Report Submission: The individual holding ratio of shares decreased by more than 1%, and there was a change in the breakdown of the held shares. Issuer: Shin Bio Pharma Co., Ltd. [Summary Table] Holding Ratio (%)
Change in shareholding report for Shin Bio Pharma (26.54% → 25.91%) by Evo Fund, etc.
Submitter: Evo Fund Submission Date and Time: February 25, 2026, 12:57 PM Submitted Document: Amendment Report (Cover Page = Amendment Report No. 17) Reporting Obligation Trigger Date: February 17, 2026 Reason for Submission of Amendment Report: The individual shareholding ratio decreased by more than 1% Issuer: <4582> Shinbio Pharmaceutical Co., Ltd. [Summary Table] Shareholding Ratio (%): 25
Market orders: Toyota and Sony Group were sold, while Sumitomo Pharma and CellSeed were bought (as of the morning session 20 days ago).
SoftBank Group sold 371,000 shares and bought 299,000 shares, Advantest sold 122,000 shares and bought 95,000 shares, Tokyo Electron sold 43,000 shares and bought 32,000 shares, Toyota sold 496,000 shares and bought 244,000 shares, Sony Group sold 641,000 shares and bought 422,000 shares, Hitachi sold 217,000 shares and bought 383,000 shares, Sumitomo Electric sold 54,000 shares and bought 38,000 shares, TDK sold 164,000 shares.
Afternoon session [Stocks that moved and stocks that were traded]
*Trend Co., Ltd. (4704) announced a share repurchase program capped at 0.92% of the total issued shares, with the stock price rising to 5832 (+241). *Takeda iP (7875) announced a stock split of 1 share into 2 shares, with the stock price at 1285 (+1101). *Post Prime (198A) elected three new directors recommended by Cybridge LLC, with the stock price at 331 (+80). *IMV Inc. (7760) was selected for JAXA's public offering "Space Strategy Fund Project (Phase 2)," with the stock price at 3905 (+205). *FRONTEO (2158) rose to 900 (+27).
